Label-Free Array Systems Global Market Report 2025

The label-free array systems market size has grown strongly in recent years. It will grow from $1.37 billion in 2024 to $1.48 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historic period can be attributed to the increasing demand for drug discovery and development, a shift toward early-stage screening in drug pipelines, the expansion of biologics and biosimilars research, the need for rapid identification of biomolecular interactions, and the rising use in lead optimization and validation.

The label-free array systems market size is expected to see strong growth in the next few years. It will grow to $1.96 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to the rising focus on personalized medicine, expansion in biomarker discovery for disease diagnostics, increased funding for life science research, availability of both government and private grants, and growing demand for non-invasive diagnostic methods. Key trends expected during this period include advancements in mass spectrometry technologies, enhancements in surface plasmon resonance systems, integration of microfluidics with label-free systems, development of high-throughput screening capabilities, and increased automation in biochemical assays.

The rising risk of lifestyle-related chronic diseases is expected to drive the growth of the label-free array systems market in the coming years. These chronic conditions, primarily caused by unhealthy behaviors such as poor diet, physical inactivity, smoking, and excessive alcohol consumption, are becoming increasingly prevalent due to more sedentary lifestyles. Desk-bound occupations and screen-based leisure activities contribute to reduced physical activity and adverse metabolic health outcomes. Label-free array systems are advanced biosensing technologies that enable real-time, high-throughput detection of biomolecular interactions without the need for fluorescent or radioactive labels. These systems are increasingly important in mitigating lifestyle-related chronic diseases by facilitating early detection, risk evaluation, and personalized prevention strategies. For example, in May 2025, the World Health Organization, a Switzerland-based intergovernmental organization, reported that around 2.5 billion adults aged 18 and over were overweight in 2022, with over 890 million classified as obese. The report also projected that by 2032, nearly 35 million children under the age of five would be affected by overweight conditions. Thus, the growing threat of lifestyle-related chronic diseases is expected to propel the label-free array systems market forward.

Leading companies in the label-free array systems market are prioritizing the development of advanced technologies, such as label-free biosensors, to streamline the testing process. Label-free biosensors are analytical tools that detect biological interactions directly, without the use of fluorescent or radioactive markers. For example, in February 2024, SPOC Proteomics Inc., a US-based life sciences company, introduced customizable SPOC protein biosensor chips. These chips enable real-time, label-free detection for up to 1,000 fully folded proteins on a compact 1.5 cm² SPR chip. The technology employs a novel method that synthesizes proteins directly from DNA in nanoliter-sized wells while simultaneously capturing and purifying them on the sensor surface. This eliminates the need for conventional recombinant protein production, reducing costs by 10 to 100 times compared to traditional techniques. Additionally, SPOC protein biosensor chips provide large-scale qualitative, quantitative, and kinetic data, making them highly suitable for high-throughput proteomic research.

In January 2023, Charles River Laboratories International Inc., a US-based biotechnology company, acquired SAMDI Tech Inc. for $50 million. This acquisition enhances Charles River’s drug discovery capabilities by integrating its scientific expertise with SAMDI Tech’s mass spectrometry-based, label-free screening technology. SAMDI Tech Inc. is a US-based producer of label-free array systems.

Major players in the label-free array systems market are Merck KGaA, Thermo Fisher Scientific Inc., Becton Dickinson and Company, Corning Incorporated, Agilent Technologies Inc., Cytiva, PerkinElmer Inc., Illumina Inc., Sartorius AG, Charles River Laboratories, Bio-Rad Laboratories Inc., Bruker Corporation, Horiba Instruments Incorporated, Tecan Group Ltd., Metrohm India Limited, Malvern Panalytical Ltd., Reichert Inc., Attana AB, NanoSPR Devices, Arrayjet, BioNavis Ltd., Biosensing Instrument Inc., GeSiM Co., Plexera LLC, Plasmetrix.

North America was the largest region in the label-free array systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in label-free array systems report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the label-free array systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Label-free array systems are analytical platforms that detect and quantify molecular interactions without requiring chemical or fluorescent labels. These systems operate by monitoring changes in physical properties such as mass, refractive index, or electrical impedance to detect the presence or behavior of biomolecules.

The primary technologies used in label-free array systems include surface plasmon resonance, biolayer interferometry, cellular dielectric spectroscopy, among others. Surface plasmon resonance (SPR) is an optical detection technique that measures real-time biomolecular interactions without labels. It utilizes various components such as sensor chips, reagents, consumables, and others, and is employed in applications like drug discovery, protein-protein interaction studies, receptor-ligand assays, thermodynamics, kinetics, and affinity mapping. The technology is used by a range of end-users including pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations, and more.

The label-free array systems market research report is one of a series of new reports that provides label-free array systems market statistics, including label-free array systems industry global market size, regional shares, competitors with a label-free array systems market share, detailed label-free array systems market segments, market trends and opportunities, and any further data you may need to thrive in the label-free array systems industry. This label-free array systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The label-free array systems market consists of revenues earned by entities by providing services such as custom assay development, contract research services, surface chemistry consulting, and method validation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The label-free array systems market also includes sales of microarray slides, detection instruments, and sample preparation kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.